venetoclaxibrutinibzanubrutinibacalabrutinibBTKiBCL2ichronic lymphocytic leukaemiaCLL
…brutinib (40.7%), acalabrutinib (30.5%), zanubrutinib (3.4%) or venetoclax (25.4%). 91.5% of them had at least one comorbidity and the med…
6articles mentioning drugs
11drug mentions
1distinct drugs extracted
0%of mentions human-reviewed
Active filtersEntity: Venetoclax ×
Venetoclax
This drug is selected. Its supporting articles are shown below.
Articles mentioning Venetoclax
6 articles · page 1 of 1ibrutinibvenetoclaxvenetoclax-inducedI+VCLLchronic lymphocytic leukaemia
…ed apoptosis.The I+V regimen consists of three 28-day cycles of ibrutinib monotherapy, followed by the addition of venetoclax from cycle …
venetoclaxhematologic malignanciesBCR::ABL1-negative myeloproliferative neoplasms (MPNs)
… and supports a combination strategy with BH3 mimetics, such as venetoclax. These findings provide a compelling rationale for ongoing prec…
Venetoclaxrenal cell carcinomapancreatic adenocarcinomaCell therapies
…hance efficacy against renal cell carcinoma.Treat NK cells with Venetoclax to improve cytoskeleton remodeling and lytic granule polarizati…
bendamustinefludarabine/cyclophosphamidevenetoclaxtocilizumabCD4CARIndiana UniversityFDAAMLacute myeloid leukemiaschronic myelomonocytic leukemia+2 more
…eived conditioning with either fludarabine/cyclophosphamide, or bendamustine, followed by CD4CAR in a 3+3 dose-escalation design. Safety and…
azacitidinevenetoclaxacute myeloid leukemiaAML
…1b, HLA-DR) on AML cells both in vitro and in vivo. Compared to azacitidine as the benchmark hypomethylating agent, the intravenous injecti…